20 years real-world data on disease burden, patient experience & unmet needs in Refractory #RheumatoidArthritis ▶️Higher glucocorticoid & opioid use ▶️Greater comorbidity & symptom burden ▶️More rheumatology visits #ACR23 👉🏽https://t.co/CAUorjQbvN by @KristinWipfler @Dr_K et al https://t.co/vx1aOZizfE

The Rheum Where It Happened! https://t.co/3gL5RLSNms

#ACR23 Abstr#0571 As there is a genetic predisposition to #SLE, can polygenic risk score distinguish SLE vs ANA+ with no disease? A study in European ancestry showed modest discrimination (AUC: 0.66). This showed other contributors are vital in SLE development @RheumNowNews https://t.co/qiFOlOxq5r

OMG! The #Gerirheum community is looking into this bias— pls fill out their survey @UnaMakris @SattuiSEMD https://t.co/Axaoo3WohH

Stop by the @rheumnow booth next to the ACR hub in the exhibit hall… we have fun trying to keep you current! BTW, watch us on the daily recap at https://t.co/kG93OYaNIx https://t.co/wuPxhyljgP

Automated #deeplearning systems #ArtificialIntelligence identify & predict joint damage in hand radiographs from #RheumatoidArthritis patients ➡️May aid in monitoring joint damage #ACR23 👉🏽https://t.co/IcoZHY6lns https://t.co/mZWg6YIUp3

ABS0433: ⭐️Older adults w/ RA less likely to receive tx w/ DMARDs despite being well tolerated and effective ➡️Retrospect, obs using Medicare data ➡️At least 66 yo old w/ new dx of late-onset RA (LORA) 🚩If no contraindications, start DMARDs early in LORA! #ACR23 @RheumNow https://t.co/ChalcgtS2O

Great work @sharoncowley01 https://t.co/llUF6REOFR https://t.co/Ej8fQlTNH0

Great talk by @DrPujaMehta1 📦 out of the box! #ACR23 #ACRambassador @ACRheum https://t.co/dmr0m6W2ZP

⭐️Real world data on use of #avacopan presented by @zach_wallace_md #vasculitis Important observations to inform the practice and management of #AAV https://t.co/gtZORcnt9t

@gurdeep_dulay I ask the same question always, why would you stop denosumab? Nothing comes close to fully ameliorating the negative consequences of doing so. Denosumab is for life, until we figure out how to safely get off it. Don't start it unless that is acceptable #ACR23

Fantastic presentation by @sharoncowley01 🚀 ~1/5 patients with PMR have US evidence of Vasculitis at time of diagnosis without clinical signs of GCA ⬆️role of US in these patients https://t.co/wSs3IB8SU7 https://t.co/mAhFDVJJ8T

The places to look for #enthesitis in #PsA in foot/ankle #ACR2023 https://t.co/KxD7i5l5gS

Super interesting study re: impact of ORAL SURVEILLANCE on prescribing Post safety report, JAK pts shifted younger w/lower comorbidities (esp CVD) I know many have mixed feelings, but I believe in the risk & support this type of shift @RheumNow Abstr0435 #ACR23 https://t.co/EBg9VOIbj1

ABS0450 ⭐️Baricitinib non-inferior as well as superior to TNFi in terms of ACR50 response @ 12w in real world csDMARD refractory RA patients ➡️open-label, T2T w/ Baricitinib (n=102) vs TNFi (n=97) ➡️DAS28-CRP remission (<0.6) in 74% of Bari vs 47% of TNFi #ACR23 @RheumNow https://t.co/yydS20hNzM